Australia's most trusted
source of pharma news
Posted 17 December 2021 PM
Like Delta before it, the Omicron variant is rewriting the timetable of the world getting to a post-pandemic normality, according to experts.
While preliminary data from small sample sizes suggests the Omicron variant could produce a less severe disease than Delta, its ability to evade the immune response combined with increased infectiousness means the disease burden could be greater than seen with previous variants.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.